Coramaze develops Tripair™, a simple, safe, and effective tricuspid valve repair system that expands access to treatment for patients with severe tricuspid regurgitation who are currently underserved by existing surgical and transcatheter options. The device is designed to lower procedural risk and broaden adoption, targeting the roughly 4.6 million patients affected worldwide, including 318 k new severe cases annually in Europe and the US.
Funding
Funding not disclosed
Founders
Product
Problem
Tricuspid regurgitation (TR) affects millions worldwide, yet over 90% of patients remain untreated because surgical risk is high and existing transcatheter options are limited to a small, highly selected group.
Solution
Coramaze’s Tripair™ is a minimally invasive transcatheter system designed to repair the tricuspid valve percutaneously. The device emphasizes procedural simplicity, safety, and effectiveness, aiming to expand treatment to patients who are ineligible for surgery and to reduce anatomical and operational barriers that limit current therapies. By using a streamlined delivery platform, Tripair enables clinicians to perform valve repair with less procedural complexity and lower risk, potentially increasing access to therapy across diverse healthcare settings. The system is positioned as an investigational solution that could broaden the eligible patient population and improve outcomes for severe TR.
Target Audience
Primary customers are interventional cardiologists and structural heart teams at hospitals and heart centers that treat patients with severe tricuspid regurgitation, particularly those unsuitable for surgical repair.
Features
- Percutaneous delivery catheter optimized for ease of navigation and deployment in the tricuspid annulus
- Simplified implantation workflow that reduces procedural steps and operator dependence
- Designed to accommodate a wide range of tricuspid anatomies, minimizing patient selection constraints
- Emphasis on safety through low-profile device architecture and controlled deployment mechanisms
- Intended for use in patients deemed high risk for conventional surgery, expanding therapeutic options